Loading...
Loading...
India's apixaban imports from UNITED STATES total $70.5K across 43 shipments from 15 foreign suppliers. ESPEE BIOPHARMA & FINECHEM LLC leads with $21.1K in import value; the top 5 suppliers together control 69.7% of this origin. Leading Indian buyers include UMEDICA LABORATORIES PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for apixaban — a diversified sourcing base with multiple active suppliers from UNITED STATES.

ESPEE BIOPHARMA & FINECHEM LLC is the leading Apixaban supplier from UNITED STATES to India, with import value of $21.1K across 5 shipments. The top 5 suppliers — ESPEE BIOPHARMA & FINECHEM LLC, SIGMAPHARM LABORATORIES, LLC, AGRACE PHARMA, SPRING BIO SOLUTION, SPRING BIO SOLUTION. — collectively account for 69.7% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ESPEE BIOPHARMA & FINECHEM LLC | $21.1K | 5 | 30.0% |
| 2 | SIGMAPHARM LABORATORIES, LLC | $10.9K | 4 | 15.5% |
| 3 | AGRACE PHARMA | $8.7K | 4 | 12.4% |
| 4 | SPRING BIO SOLUTION | $4.2K | 2 | 6.0% |
| 5 | SPRING BIO SOLUTION. | $4.1K | 3 | 5.8% |
| 6 | RAFF & HALL PHARMACY | $4.0K | 1 | 5.7% |
| 7 | REGIONAL PHARMACY | $3.2K | 2 | 4.5% |
| 8 | ASAMAN | $2.3K | 2 | 3.3% |
| 9 | AGRACE PHARMA. | $2.2K | 1 | 3.1% |
| 10 | NewLife Medicals (USA). Inc. | $1.5K | 1 | 2.1% |
| 11 | AMSTERDAM PHARMA (APTEKA RX INC) | $1.4K | 2 | 2.0% |
| 12 | ELITE LABORATORIES INC | $1.4K | 2 | 2.0% |
| 13 | AMSTERDAM PHARMA (APTEKA RX INC.) | $1.4K | 2 | 1.9% |
| 14 | SIGMAPHARM LABORATORIES LLC | $1.3K | 4 | 1.8% |
| 15 | NEWLIFE MEDICALS (USA). INC. | $758 | 1 | 1.1% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | UMEDICA LABORATORIES PRIVATE LIMITED | $16.4K | 2 | 23.2% |
| 2 | ECRON ACUNOVA LIMITED | $12.2K | 8 | 17.3% |
| 3 | MANKIND PHARMA LIMITED | $4.2K | 2 | 6.0% |
| 4 | DR.REDDY'S LABORATORIES LTD | $4.2K | 2 | 5.9% |
| 5 | CIPLA LIMITED | $4.1K | 3 | 5.8% |
| 6 | EMCURE PHARMACEUTICALS LIMITED | $4.0K | 1 | 5.7% |
| 7 | DR REDDYS LABORATORIES LIMITED | $3.8K | 1 | 5.4% |
| 8 | INDOCO REMEDIES LIMITED | $3.7K | 2 | 5.2% |
| 9 | TORRENT PHARMACEUTICALS LTD | $3.2K | 2 | 4.5% |
| 10 | CENTAUR PHARMACEUTICALS PRIVATE LIMITED | $2.8K | 2 | 4.0% |
| 11 | MYLAN LABORATORIES LIMITED | $2.3K | 2 | 3.3% |
| 12 | AZURITY PHARMACEUTICALS INDIA LLP | $2.3K | 2 | 3.2% |
| 13 | EXTROVIS PRIVATE LIMITED | $2.2K | 3 | 3.1% |
| 14 | ACTIMUS BIOSCIENCES PRIVATE LIMITED | $1.4K | 3 | 2.0% |
| 15 | SLAYBACK PHARMA INDIA LLP | $1.4K | 2 | 1.9% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Apixaban suppliers from UNITED STATES to India include ESPEE BIOPHARMA & FINECHEM LLC, SIGMAPHARM LABORATORIES, LLC, AGRACE PHARMA. The leading supplier is ESPEE BIOPHARMA & FINECHEM LLC with import value of $21.1K USD across 5 shipments. India imported Apixaban worth $70.5K USD from UNITED STATES in total across 43 shipments.
India imported Apixaban worth $70.5K USD from UNITED STATES across 43 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Apixaban sourced from UNITED STATES include UMEDICA LABORATORIES PRIVATE LIMITED, ECRON ACUNOVA LIMITED, MANKIND PHARMA LIMITED. The largest buyer is UMEDICA LABORATORIES PRIVATE LIMITED with $16.4K in imports across 2 shipments.
The total value of Apixaban imports from UNITED STATES to India is $70.5K USD, across 43 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
43 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists